Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,259 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Disease Clear all
Not listed Phase 4 Interventional

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

NCT01793519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Infliximab, Adalimumab, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 10:36 PM EDT
Not listed No phase listed Observational

Physical Activity Monitoring in Myasthenia Gravis

NCT06277830
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Wearable sensor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 4 Interventional

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902
View directory record Official record
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

NCT03427151
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
IPP-201101
Drug
Lead sponsor
ImmuPharma
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Leandro, California • Aventura, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT03567057
View directory record Official record
Conditions
Multiple Sclerosis, Walking Impairment
Interventions
ADS-5102, 274 mg
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
82
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 10:36 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

NCT07773727
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Miami, Florida • Pontiac, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:36 PM EDT
Not listed Not applicable Interventional

Reinventing Yourself With Multiple Sclerosis (MS)

NCT05195320
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Reinvention with MS
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 21, 2026, 10:36 PM EDT
Completed No phase listed Observational

Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study

NCT03776682
View directory record Official record
Conditions
Myocardial Inflammation, Rheumatoid Arthritis, Coronary Artery Disease, Myocardial Strain
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 21, 2026, 10:36 PM EDT
Terminated No phase listed Observational

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Discontinuation of eltrombopag
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

NCT04261790
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
114
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 21, 2026, 10:36 PM EDT
Completed No phase listed Observational

MSPT Device Usability Study

NCT02664324
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 21, 2026, 10:36 PM EDT
Not listed Phase 3 Interventional

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

NCT00053560
View directory record Official record
Conditions
Lupus
Interventions
Prasterone (GL701)
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 21, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Imeroprubart, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Virtual Reality Meditation for Fatigue

NCT04804462
View directory record Official record
Conditions
Fatigue, Rheumatoid Arthritis
Interventions
Virtual Reality Meditation
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 21, 2026, 10:36 PM EDT
Completed No phase listed Observational

Plasma Exchange for Autoimmune Autonomic Failure

NCT00359346
View directory record Official record
Conditions
Plasma Exchange, Autonomic Failure
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:36 PM EDT
Completed No phase listed Observational

A Clinical Investigation of the Balance® Microplasty™ Hip System

NCT00699088
View directory record Official record
Conditions
Osteoarthritis, Hip, Rheumatoid Arthritis, Avascular Necrosis
Interventions
Not listed
Lead sponsor
Biomet Orthopedics, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Fredericksburg, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 10:36 PM EDT
Completed No phase listed Observational

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

NCT00461396
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon-1beta (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 21, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

NCT01110746
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Viaject 7, LISPRO
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 21, 2026, 10:36 PM EDT
Terminated No phase listed Observational

Clinical Evaluation of the TITAN™ Total Shoulder System

NCT03245320
View directory record Official record
Conditions
Arthritis, Arthritis, Degenerative, Rheumatoid Arthritis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Avascular Necrosis, Joint Instability, Joint Trauma, Dislocation, Shoulder, Pain, Shoulder
Interventions
Integra TITAN™ Total Shoulder Generation 1.0
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 10:36 PM EDT